2-Substituted oxazolyl and thiazolyl amino acids are suitable P1 surrogates for new SARS-CoV-2 main protease inhibitors | Synapse
June 4, 2026Open Access
2-Substituted oxazolyl and thiazolyl amino acids are suitable P1 surrogates for new SARS-CoV-2 main protease inhibitors
Key Points
To synthesize new amino acid building blocks for use in SARS-CoV-2 main protease inhibitors.
Synthesis of enantiopure heteroazole amino acids from commercially available materials
Incorporation of new amino acid structures into main protease inhibitors
Evaluation as alternatives to cyclic glutamine
New heteroazole amino acids effectively replaced cyclic glutamine in structures
Demonstrated potential for enhancing inhibitor efficacy against SARS-CoV-2 main protease
Showed favorable binding properties and stability compared to traditional amino acids.
Abstract
Synthesis of enantiopure heteroazole amino acid building blocks from commercially available materials for incorporation into SARS-CoV-2 M pro inhibitors as alternatives to the cyclic glutamine P1.